{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2025.11.27.25341159v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2025.11.27.25341159v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2025.11.27.25341159v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EABSTRACT\u003C\/h2\u003E\u003Cp id=\u0022p-2\u0022\u003EMany patients with painful diabetic neuropathy (PDN) do not achieve meaningful pain relief with standard of care. MEDI7352 is a unique bispecific fusion protein targeting two key mediators of pain, TNF\u03b1 and NGF (at relatively low levels of suppression). We report a randomized, double-blind, placebo-controlled, Phase-2a study (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03755934\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT03755934\u003C\/a\u003E\/EudraCT-2018-002523-42) assessing efficacy and safety of MEDI7352 in patients aged \u226518 years with inadequately controlled PDN. Patients remained on background standard-of-care treatment and were randomized to placebo (n=54) or MEDI7352 intravenously (5\u03bcg\/kg [n=6], 150\u03bcg\/kg [n=16], 450\u03bcg\/kg [n=36]). Primary endpoint was change in pain scores from baseline to Week 12 vs placebo on a numeric rating scale (NRS). Key secondary outcomes included change in pain scores from baseline at visits prior to Week 12 and responder rates. Of 112 patients randomized, 107 received \u22651 dose study medication; mean age (standard deviation [SD]) in the modified-intent-to-treat population was 60.5 (9.34) years; 62.6% males, 37.4% females. With MEDI7352 450\u03bcg\/kg, change from baseline in pain scores at Week 12 vs placebo was: \u22121.39 [95% CI: \u22122.19 to \u22120.58], \u003Cem\u003Ep\u003C\/em\u003E=0.0009; at Week 12, mean (SD) pain scores decreased vs baseline by \u22122.70 (2.08); 66.7% of patients experienced decreased pain by \u226530% (\u003Cem\u003Ep\u003C\/em\u003E=0.0311 vs. placebo); 42.4% experienced decrease \u226550% (\u003Cem\u003Ep\u003C\/em\u003E=0.0029). MEDI7352 safety was similar to placebo; no adjudicated Rapidly Progressing Osteoarthritis (RPOA) type-1 or RPOA type-2 events were observed in any group. MEDI7352 achieved statistically significant and clinically meaningful pain reduction in patients with PDN vs placebo and provides an opportunity to change the paradigm for challenging-to-treat pain.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EINTRODUCTION\u003C\/h2\u003E\u003Cp id=\u0022p-16\u0022\u003EAn estimated 529 million people were living with diabetes in 2021, and this number is expected to more than double to about 1.31 billion by 2050 (\u003Cem\u003E\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E\u003C\/em\u003E). Pain is prevalent in around 10% to 20% of patients with diabetes, and in around 40% to 50% of those with diabetic neuropathy (\u003Cem\u003E\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u003C\/em\u003E). The majority have features of chronic sensorimotor neuropathy (\u003Cem\u003E\u003Ca id=\u0022xref-ref-2-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E\u003C\/em\u003E). Painful diabetic neuropathy (PDN) is often experienced as a burning, stabbing, pricking or aching sensation that is chronic and difficult to manage; it carries a substantial physical, social, and economic burden. Patients frequently experience anxiety, depression, and sleep disturbance. It is estimated that almost half of these patients do not receive any treatment for their pain.\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EFirst-line treatments for PDN include tricyclic antidepressants, pregabalin, gabapentin, and duloxetine; other treatments include opioids, topical treatments (lidocaine and capsaicin), and non-pharmacological treatments including transcutaneous electrical nerve stimulation and acupuncture. All of these treatments have limitations, and variable efficacy and responder rates; many carry serious safety concerns and the potential for abuse and dependence. With standard therapies, the number needed to treat to achieve at least 50% pain relief is around 5 to 6 (\u003Cem\u003E\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/em\u003E). Despite the poly-pharmacy approach to PDN management, fewer than 20% of patients can expect to achieve meaningful pain relief with current treatment paradigms. There is therefore a high need for new drugs for the treatment of PDN that offer an improved balance of pain relief and tolerability.\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EMEDI7352 is a novel bispecific fusion protein uniquely designed to engage two key biological mediators, Nerve Growth Factor (NGF) and Tumor Necrosis Factor-\u03b1 (TNF\u03b1), both of which are considered to play an important role in sensitization of the nervous system and in pain pathophysiology (\u003Cem\u003E\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/em\u003E). Tumor necrosis factor receptor blockers have a well-established role for disease modification in the management of rheumatoid arthritis and other inflammatory joint diseases, in which pain is often an important component (\u003Cem\u003E\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/em\u003E); TNF\u03b1 blockers are thought to be at least partially efficacious in clinical neuropathic pain (\u003Cem\u003E\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/em\u003E). For anti-NGF antibodies, several clinical studies have demonstrated efficacy in osteoarthritis (OA) and chronic lower back pain (\u003Cem\u003E\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E\u003C\/em\u003E). However, despite significant analgesic benefits, studies have been limited to lower doses \u2013 partly due to the rare but serious occurrences of rapidly progressive osteoarthritis (RPOA), resulting in earlier-than-expected joint replacements for a small number of patients. This condition appears to be dose-related and exacerbated by co-administration of non-steroidal anti-inflammatory drugs (NSAIDs). Furthermore, RPOA is only observed after chronic dosing, appearing after approximately 24 weeks of exposure, with an unclear peak incidence (\u003Cem\u003E\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\u003C\/em\u003E). These effects have largely been responsible for previous terminations of further development of anti-NGF therapies for OA in humans. Anti-NGF therapies are approved for OA pain in dogs and cats (bedinvetmab and frunevetmab, respectively), with an adequate safety profile (\u003Cem\u003E\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E\u003C\/em\u003E) and positive post-approval data showing improvements in quality of life (\u003Cem\u003E\u003Ca id=\u0022xref-ref-25-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-25\u0022\u003E25\u003C\/a\u003E\u003C\/em\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EThe mechanism underlying the observed joint safety events remains poorly understood (\u003Cem\u003E\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E\u003C\/em\u003E). One possible explanation could be NGF-related effects on cartilage formation and bone repair (\u003Cem\u003E\u003Ca id=\u0022xref-ref-27-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E\u003C\/em\u003E). There is pre-clinical evidence supporting this hypothesis: signaling via the NGF receptor promotes repair and reduces inflammation in osteoarthritic joints in mice via inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB) (which mediates the induction of TNF\u03b1). Blocking this pathway resulted in increased NF-\u03baB, leading to impaired bone formation and increased bone resorption (\u003Cem\u003E\u003Ca id=\u0022xref-ref-28-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-28\u0022\u003E28\u003C\/a\u003E\u003C\/em\u003E). Notably, anti-TNF\u03b1 therapy has shown potential to protect joints in patients with rheumatoid arthritis, limiting radiographic joint damage and the progression of structural damage (\u003Cem\u003E\u003Ca id=\u0022xref-ref-29-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-29\u0022\u003E29\u003C\/a\u003E\u003C\/em\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EMEDI7352 is the first bispecific, biologic molecule to be tested in chronic pain indications. Its novel mechanism, targeting both the TNF\u03b1 and NGF signaling pathways, distinguishes it from regular anti-NGF approaches and may therefore offer a differentiated safety profile as well as the potential for improved efficacy. We also hypothesized that the bispecific approach would provide improved analgesic efficacy with correspondingly lower NGF suppression than molecules targeting NGF alone.\u003C\/p\u003E\u003Cp id=\u0022p-21\u0022\u003EAdministration of MEDI7352 produced a significant antihyperalgesic effect in pre-clinical \u003Cem\u003Ein vivo\u003C\/em\u003E models of inflammatory and neuropathic pain, at doses at which its individual separate components remained inactive. Target engagement pharmacokinetics\/pharmacodynamics (PK\/PD) modelling of preclinical data suggested that MEDI7352 may be able to achieve efficacy by suppressing less than 10% of circulating NGF, resulting from synergy achieved through sequestration of both NGF as well as TNF\u03b1 (\u003Cem\u003E\u003Ca id=\u0022xref-ref-30-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-30\u0022\u003E30\u003C\/a\u003E\u003C\/em\u003E). MEDI7352 therefore represents a potential analgesic mechanism that could avoid unwanted effects associated with higher levels of NGF suppression (hence improving safety), while maximizing analgesic benefits (\u003Cem\u003E\u003Ca id=\u0022xref-ref-30-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-30\u0022\u003E30\u003C\/a\u003E\u003C\/em\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EWe also previously assessed MEDI7352 in a randomized, double-blind, placebo controlled, interleaved single ascending dose (SAD) and multiple ascending dose (MAD), multi-center Phase 1 study in participants with painful osteoarthritis of the knee (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02508155\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT02508155\u003C\/a\u003E; EudraCT identifier 2015-000267-13) (\u003Cem\u003E\u003Ca id=\u0022xref-ref-31-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E\u003C\/em\u003E). While the primary purpose of that study was to investigate safety, tolerability, PK and PD of MEDI7352, exploratory endpoints also included clinical PD measures of pain. Numeric rating scale (NRS) pain scores and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores indicated that MEDI7352 had the potential to achieve dose-related analgesic effects when compared with placebo, in osteoarthritis; the safety profile was good, with no RPOA observed (\u003Cem\u003E\u003Ca id=\u0022xref-ref-31-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E\u003C\/em\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EHere, we report the outcomes of a randomized, double-blind, placebo-controlled, four-stage Phase 2a exploratory, dose-response study (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03755934\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT03755934\u003C\/a\u003E; EudraCT identifier 2018-002523-42) to assess the efficacy and safety of MEDI7352 in patients with PDN.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ERESULTS\u003C\/h2\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatients\u003C\/h3\u003E\u003Cp id=\u0022p-24\u0022\u003EThe study design is summarized in Fig S1. Altogether, 354 patients were screened; 112 patients were enrolled and randomized, and 107 patients received at least 1 dose of study medication (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFig. 1\u003C\/a\u003E.)\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022CONSORT Diagram Screening Population includes all subjects who provided informed consent and demographic and\/or baseline screening assessments. mITT = modified intent-to-treat; PK = Pharmacokinetic.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-320956754\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;span xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot; class=\u0026quot;caption-title\u0026quot;\u0026gt;CONSORT Diagram\u0026lt;\/span\u0026gt; Screening Population includes all subjects who provided informed consent and demographic and\/or baseline screening assessments. mITT = modified intent-to-treat; PK = Pharmacokinetic.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022308\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022308\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ECONSORT Diagram\u003C\/span\u003E\u003Cp id=\u0022p-25\u0022 class=\u0022first-child\u0022\u003EScreening Population includes all subjects who provided informed consent and demographic and\/or baseline screening assessments. mITT = modified intent-to-treat; PK = Pharmacokinetic.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-26\u0022\u003EThe mean (standard deviation [SD]) age of patients in the modified intent-to-treat (mITT) population was 60.5 (9.3) years with no notable differences among treatment groups (\u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E). Most patients (61.7%) were \u226518 to \u0026lt;65 years old. Patients were mostly male (62.6% males versus 37.4% females); 85.0% of the females were postmenopausal.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/1115250\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/1115250\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/1115250\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EDemographics and baseline characteristics (mITT\/Safety Population)\u003C\/span\u003E\u003Cp id=\u0022p-27\u0022 class=\u0022first-child\u0022\u003EPrior medications were defined as medications that started before first dose of study, whether they were stopped before first dose of study medication or not. Prior medications by ATC level 2. ATC = Anatomical Therapeutic Chemical; BMI = body mass index; mITT = Modified Intent-to-treat; SD = standard deviation.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-28\u0022\u003EIn the mITT population, 17 patients (15.9%) had a diagnosis of OA, which mostly affected the spine (11 patients, 10.3%) and the knees (5 patients, 4.7%). Most of the patients with OA were randomly assigned to the placebo group (13 patients, 24.1%); none of the patients in the MEDI7352 150 \u03bcg\/kg group had OA. Osteoarthritis was diagnosed in 1 of 4 patients (25.0%) in the MEDI7352 5 \u03bcg\/kg group and 3 of 35 patients (8.6%) in the MEDI7352 450 \u03bcg\/kg group. However, in line with the study exclusion criteria, the OA was not considered clinically significant in any of the patients.\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EOf all 107 patients in the safety population, 100 patients (93.5%) had type 2 diabetes mellitus, 6 patients (5.6%) had type 1 diabetes mellitus, and 1 patient (0.9%) had unspecified diabetes mellitus.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EAnalgesics and drugs used in diabetes were administered as prior medication to all patients in the MEDI7352 groups, and almost all patients in the placebo group (N=54; 53 patients received analgesics [98.1%], 51 patients received drugs used in diabetes [94.4%]) (\u003Ca id=\u0022xref-table-wrap-1-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E). The most commonly reported analgesic medications were gabapentin, pregabalin, paracetamol, duloxetine, and amitriptyline, and the most commonly reported drugs used in diabetes were metformin, gliclazide, empagliflozin, and a form of insulin.\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EThe same proportion of patients who took analgesics and drugs used in diabetes as prior medication also took them as concomitant medication during the course of the trial: 100% of patients in all MEDI7352 groups took medications in both drug classes; in the placebo group, 98.1% of patients took analgesics, and 94.4% took drugs used in diabetes (Table S1).\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EIn terms of the disease under study (PDN) and concomitant diseases, age, body mass index, prior and concomitant medications, the recruited population adequately represented the target population for MEDI7352, and was appropriate for the type of study; demographics and baseline characteristics were either similar among the treatment groups, or the observed small differences were not considered to have a potential influence on results and their interpretation.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEfficacy\u003C\/h3\u003E\u003Cp id=\u0022p-33\u0022\u003EThe primary objective was evaluated by assessing the change in the weekly average of the average daily pain scores from the baseline week to Week 12 of MEDI7352 compared with placebo, as measured on an 11-point (0 to 10) NRS (referred to as \u2018pain score[s]\u2019 hereafter). At baseline, the mean (SD) pain score was similar in all treatment groups; in the overall population, the mean (SD) pain score was 6.69 (1.23) (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E). MEDI7352 450 \u03bcg\/kg provided a statistically significant and clinically meaningful change from baseline in pain scores at Week 12 compared with placebo (MEDI7352 450 \u03bcg\/kg vs placebo: \u22121.39 [95% Confidence Interval (CI): \u22122.19 to \u22120.58]; ***\u003Cem\u003Ep\u003C\/em\u003E=0.0009; primary analysis of covariance analysis [ANCOVA]; Last Observation Carried Forward [LOCF]; mITT) (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2A\u003C\/a\u003E.). For MEDI7352 150 \u03bcg\/kg, change from baseline in pain scores at Week 12 compared with placebo was 0.72 (95% CI: \u22120.36 to 1.79); \u003Cem\u003Ep\u003C\/em\u003E= 0.1878. For MEDI7352 5 \u03bcg\/kg, it was \u22121.96 (95% CI: \u22123.87 to \u22120.06); \u003Cem\u003Ep\u003C\/em\u003E=0.0437); however, this effect was not considered reliable due to the small sample size in this group (N=4).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Key efficacy outcomes A) Change in NRS pain scores from baseline (mean [SD]); MEDI7352 450 \u0026#x3BC;g\/kg vs placebo: \u0026#x2212;1.39 [95% CI: \u0026#x2212;2.19 to \u0026#x2212;0.58], ***p=0.0009 (primary ANCOVA); LOCF, mITT. B and C) Percentage of patients (SD) showing \u0026#x2265;30% or \u0026#x2265;50% reduction in daily pain NRS at Week 12 compared with baseline (p values: Cochran-Mantel Haenszel), respectively; Observed Cases, mITT. D) Daily Sleep Interference Score; mean (SD); *p=0.0343 vs. placebo (mixed model for repeated measures analysis); Observed Cases, mITT. ANCOVA = analysis of covariance; DSIS = Daily Sleep Interference Score; mITT = modified intent-to-treat; NRS = Numeric Rating Scale; SD, Standard Deviation.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-320956754\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Key efficacy outcomes\u0026lt;\/span\u0026gt; A) Change in NRS pain scores from baseline (mean [SD]); MEDI7352 450 \u0026#x3BC;g\/kg vs placebo: \u0026#x2212;1.39 [95% CI: \u0026#x2212;2.19 to \u0026#x2212;0.58], ***\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;=0.0009 (primary ANCOVA); LOCF, mITT. B and C) Percentage of patients (SD) showing \u0026#x2265;30% or \u0026#x2265;50% reduction in daily pain NRS at Week 12 compared with baseline (\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; values: Cochran-Mantel Haenszel), respectively; Observed Cases, mITT. D) Daily Sleep Interference Score; mean (SD); *\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;=0.0343 vs. placebo (mixed model for repeated measures analysis); Observed Cases, mITT. ANCOVA = analysis of covariance; DSIS = Daily Sleep Interference Score; mITT = modified intent-to-treat; NRS = Numeric Rating Scale; SD, Standard Deviation.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Fig. 2.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022294\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Fig. 2.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022294\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Fig. 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/11\/30\/2025.11.27.25341159\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFig. 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EKey efficacy outcomes\u003C\/span\u003E\u003Cp id=\u0022p-34\u0022 class=\u0022first-child\u0022\u003EA) Change in NRS pain scores from baseline (mean [SD]); MEDI7352 450 \u03bcg\/kg vs placebo: \u22121.39 [95% CI: \u22122.19 to \u22120.58], ***\u003Cem\u003Ep\u003C\/em\u003E=0.0009 (primary ANCOVA); LOCF, mITT. B and C) Percentage of patients (SD) showing \u226530% or \u226550% reduction in daily pain NRS at Week 12 compared with baseline (\u003Cem\u003Ep\u003C\/em\u003E values: Cochran-Mantel Haenszel), respectively; Observed Cases, mITT. D) Daily Sleep Interference Score; mean (SD); *\u003Cem\u003Ep\u003C\/em\u003E=0.0343 vs. placebo (mixed model for repeated measures analysis); Observed Cases, mITT. ANCOVA = analysis of covariance; DSIS = Daily Sleep Interference Score; mITT = modified intent-to-treat; NRS = Numeric Rating Scale; SD, Standard Deviation.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/1115249\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/1115249\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/1115249\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EChange in weekly average of average daily pain NRS score, compared with baseline (mITT; LOCF)\u003C\/span\u003E\u003Cp id=\u0022p-35\u0022 class=\u0022first-child\u0022\u003E[1] Baseline defined as the average of the \u2018non-missing\u2019 DPS within the seven-day period prior to randomization i.e., Day \u22127 to Day \u22121, inclusive. CFB = Change from Baseline; DPS = Daily Pain Score; LOCF = Last Observation Carried Forward; NRS = Numeric Rating Scale; SD = standard deviation.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-36\u0022\u003EAt Week 12, the mean and the median pain scores in the placebo group had decreased from baseline by \u22121.24 (SD: 1.73) and \u22120.87, respectively (\u003Ca id=\u0022xref-table-wrap-2-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E). In the MEDI7352 5 \u03bcg\/kg group, the mean and the median pain scores dropped by \u22123.39 (SD: 1.96) and \u22123.38 points, respectively; again, this was not considered reliable due to the small sample size. In the MEDI7352 150 \u03bcg\/kg group, the mean and the median pain scores decreased slightly less than in the placebo group, by \u22120.62 (SD: 1.04) and \u22120.38 points, respectively. In the MEDI7352 450 \u03bcg\/kg group, the mean and the median pain scores decreased by \u22122.70 (SD: 2.08) and \u22123.14, respectively, compared with baseline (\u003Ca id=\u0022xref-fig-2-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2A\u003C\/a\u003E and \u003Ca id=\u0022xref-table-wrap-2-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E). Pain scores gradually decreased over time in all groups during Weeks 2 to 10 (and 12), including in the placebo group, with the largest reliable impact observed in the MEDI7352 450 \u03bcg\/kg group (\u003Ca id=\u0022xref-table-wrap-2-4\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-37\u0022\u003EAmong all treatment groups (disregarding MEDI7352 5 \u03bcg\/kg due to small sample size), the highest proportion of patients with \u226530% or \u226550% improvement at Week 12 was seen in the MEDI7352 450 \u03bcg\/kg group, in which 66.7% of patients had a decrease of pain by \u226530% (\u003Cem\u003Ep\u003C\/em\u003E=0.0311 vs. placebo; Cochran-Mantel Haenszel), and 42.4% had a decrease of pain by \u226550% (\u003Cem\u003Ep\u003C\/em\u003E=0.0029 vs. placebo;\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003ECochran-Mantel Haenszel) (\u003Ca id=\u0022xref-fig-2-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2B\u003C\/a\u003E and \u003Ca id=\u0022xref-fig-2-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003E2C\u003C\/a\u003E; Tables S2 and S3). This indicates a statistically significant association between the observed improvement from baseline and the treatment.\u003C\/p\u003E\u003Cp id=\u0022p-39\u0022\u003EDaily sleep interference was gradually reduced (suggesting improved sleep) in all treatment groups, including placebo. The most positive impact on sleep interference that can be considered reliable was seen in the MEDI7352 450 \u03bcg\/kg group; statistical analysis for this group suggested a significant association between the observed effect and treatment at Week 12 (MEDI7352 450 \u03bcg\/kg vs placebo \u22121.00 [95% CI: \u22121.93 to \u22120.08]; \u003Cem\u003Ep\u003C\/em\u003E=0.0343; mixed model for repeated measures analysis; Observed Cases; mITT; \u003Ca id=\u0022xref-fig-2-5\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2D\u003C\/a\u003E). The effect seen in the MEDI7352 5 \u03bcg\/kg group was not considered reliable, due to low sample size (\u003Ca id=\u0022xref-fig-2-6\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFig. 2D\u003C\/a\u003E and Table S4).\u003C\/p\u003E\u003Cp id=\u0022p-40\u0022\u003EThe total score for Galer neuropathic pain scale generally decreased from baseline, and the decrease was more pronounced in the MEDI7352 groups, particularly with the 450 \u03bcg\/kg dose group. However, high interindividual variability was observed; for some patients, across all treatment groups (except the MEDI7352 5 \u03bcg\/kg group), an increase in the total score was seen during the study (worsening pain). Statistical analysis at Week 12 (not reported) did not suggest a significant association between the treatment and observed Change from Baseline (CFB) in any of the treatment groups (Table S5).\u003C\/p\u003E\u003Cp id=\u0022p-41\u0022\u003EThe proportion of patients who had \u2018improved\u2019, \u2018much improved\u2019 or \u2018very much improved\u2019 on the Patient Global Impression of Change (PGIC) increased slightly over time across all treatment groups, and the statistical analysis (not reported) did not suggest an association between treatment and changes in the PGIC assessments (Table S6).\u003C\/p\u003E\u003Cp id=\u0022p-42\u0022\u003EIn general, the results of 36-Item Short-form Health Survey (SF-36) did not change during the study. CFB data showed a slight improvement in the physical component score in all treatment groups; slight worsening in the mental component score was seen in all treatment groups except the MEDI7352 5 \u03bcg\/kg group; change in general health (categorical data) was improved across all treatment groups, but particularly in the MEDI7352 150 and 450 \u03bcg\/kg groups. However, no statistically significant differences between treatment groups were observed (not reported), except for the MEDI7352 150 \u03bcg\/kg group, in which a slight improvement on mental health was estimated \u2013 which was not considered reliable due to low sample size (Table S7).\u003C\/p\u003E\u003Cp id=\u0022p-43\u0022\u003ESimilar proportions of patients took rescue medication in the placebo group (13.0%) and in the MEDI7352 150 \u03bcg\/kg group (14.3%), with a slightly lower proportion for the MEDI7352 450 \u03bcg\/kg group (8.6%) (Table S8). No patients in the MEDI7352 5 \u03bcg\/kg group took a rescue medication.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAdverse events\u003C\/h3\u003E\u003Cp id=\u0022p-44\u0022\u003ETreatment-emergent adverse events (TEAEs) were reported with higher incidence in patients who received MEDI7352 (69.8%) compared with patients who received placebo (55.6%), with no specific trends identified in TEAEs reported to account for the imbalance (\u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E). Most of the TEAEs were considered unrelated to the investigational product (IP). Reported TEAEs were mostly mild and moderate; severe TEAEs were reported for 1 patient who received placebo (lung abscess) and 1 patient who received MEDI7352 450 \u03bcg\/kg (allodynia).\u003C\/p\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/1115251\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/1115251\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/1115251\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EOverview of Adverse Events (Safety Population)\u003C\/span\u003E\u003Cp id=\u0022p-45\u0022 class=\u0022first-child\u0022\u003EResults shown are n\/N; some patients experienced multiple events. AE = adverse event; IP = investigational product; SAE = serious adverse event; SOC = System organ class; PT = preferred term; TEAE = treatment-emergent adverse event; NSD = Nervous system disorder.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-46\u0022\u003EA serious adverse event was reported for 1 patient in the placebo group, who experienced severe lung abscess (not related to IP). No TEAE was life-threatening or fatal. Nine patients (8.4%) discontinued IP due to a TEAE: 5 in the placebo group (9.3%) and 4 in the All MEDI7352 group (7.5%). Two patients in the All MEDI7352 group developed 3 adverse events of special interest of infusion-related reaction, including 1 patient in whom this event led to discontinuation of treatment with the IP. There were no joint safety adverse events of special interest, and no adjudicated RPOA type 1 or RPOA type 2 events were observed in any group.\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003EThe most commonly reported TEAEs were reported under the \u201cInfections and infestations\u201d system organ class (SOC) and included events such as upper respiratory tract infection, urinary tract infection and nasopharyngitis. These events were reported in a smaller proportion of patients who received MEDI7352. Common TEAEs under the \u201cNervous system disorders\u201d SOC, such as headache, were reported with similar incidence between the placebo group and the All MEDI7352 group; however, paraesthesia was reported only in the All MEDI7352 group, not in the placebo group (2 patients vs 0 patients). Other common events included events under the \u201cGastrointestinal disorders\u201d SOC, such as diarrhoea, which were more common in the placebo group. Events reported with a \u22653.0% greater incidence in the All MEDI7352 group than in the placebo group were muscle spasms, alanine aminotransferase increased, blood glucose decreased, infusion related reaction, paraesthesia, and toothache.\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003ENo clinically relevant observations or trends were found in the clinical chemistry, haematology, coagulation, urinalysis, vital signs, and electrocardiogram evaluations. Results of physical and neurological exams, Total Neuropathy Score-Nurse, motor and sensory nerve conduction studies and strength and tendon reflexes were in concordance with usual findings in patients with PDN. No relevant changes were observed in these parameters throughout the study.\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003EEvaluation of hypersensitivity\/anaphylactic reactions, injection-site reactions, and infusion-related reactions, drug-induced liver injury and infection risk did not raise any concerns.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EOverall, the safety profile of MEDI7352 was similar to that of placebo, with no unexpected safety findings.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPharmacokinetic, pharmacodynamic, immunogenicity and dose-response assessments\u003C\/h3\u003E\u003Cp id=\u0022p-51\u0022\u003EA descriptive summary is included in the Supplementary Materials. Of note, the prevalence of anti-drug antibodies (ADAs) in this study was high, with 75.5% of patients having treatment-emergent ADAs. The presence of ADAs appeared to impact both the PK and PD of MEDI7352 (Fig. S2\u2013S5 and Table S9). Only relatively limited PK samples were collected in this study for each patient; these data were therefore analysed by population PK methods instead \u2013 as part of a combined population PK analysis of several MEDI7352 studies (\u003Cem\u003E\u003Ca id=\u0022xref-ref-32-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-32\u0022\u003E32\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-33-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E\u003C\/em\u003E). There was no clear impact of ADA on downstream efficacy or safety, despite the impact on PD.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDISCUSSION\u003C\/h2\u003E\u003Cp id=\u0022p-52\u0022\u003EWe studied MEDI7352, a novel bispecific fusion protein targeting NGF and TNF\u03b1, and showed that at a dose of 450 \u03bcg\/kg it provided a statistically significant and clinically meaningful reduction of pain in addition to standard of care, compared with placebo, 12 weeks after initiation of treatment. Pain decreased gradually over time, and for each dose this was approximately linear over time, independent of co-medication type or baseline pain level; the low numbers of patients in some of the treatment groups limited our ability to detect a dose-response. The benefit also appeared to persist 4\u20136 weeks after the final dose. More than 60% of patients who received the dose of 450 \u03bcg\/kg reported at least a 30% decrease in pain, and more than 40% of patients receiving this dose reported at least a 50% decrease in pain. We also observed an improvement in sleep that is considered clinically meaningful (\u003Cem\u003E\u003Ca id=\u0022xref-ref-34-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-34\u0022\u003E34\u003C\/a\u003E\u003C\/em\u003E). These results suggest that targeting both NGF and TNF\u03b1 delivers significant efficacy (in addition to standard of care medication) that is sustained beyond the half-life of the drug (\u003Cem\u003E\u003Ca id=\u0022xref-ref-31-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-33-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E\u003C\/em\u003E). The mechanism underlying this remains unclear, but it implies that there is a lasting effect that is initiated by the suppression of these pathways.\u003C\/p\u003E\u003Cp id=\u0022p-53\u0022\u003EThis was a difficult-to treat population of patients, with significant ongoing pain who were already refractory to standard of care medications. Inadequate response to pharmacological treatments is a considerable unmet need in patients with neuropathic pain; modest efficacy, large responses to placebo, heterogeneity in diagnostic criteria, and suboptimal profiling of phenotype likely account for modest trial outcomes (\u003Cem\u003E\u003Ca id=\u0022xref-ref-35-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-35\u0022\u003E35\u003C\/a\u003E\u003C\/em\u003E). Notably, in our study there was no washout period for prior pain medications before randomization, and all groups (including the placebo group) continued to receive other pain medications as part of their background standard-of-care. The improvement we observed in pain scores is consistent with observations from our previous Phase 1 study in participants with painful OA of the knee (\u003Cem\u003E\u003Ca id=\u0022xref-ref-31-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E\u003C\/em\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-54\u0022\u003EThe safety profile of MEDI7352 was similar to that of placebo, with no unexpected safety findings. RPOA and destructive changes in the joints have been identified as a dose-related class effect for anti-NGF monoclonal antibodies (\u003Cem\u003E\u003Ca id=\u0022xref-ref-27-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-36-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-36\u0022\u003E36\u003C\/a\u003E\u003C\/em\u003E). No patient experienced a TEAE of OA or other joint degenerative disease during the study, and no predefined adverse events of special interest were identified in this category. Patients had been excluded if they had clinically significant OA affecting a major joint in the upper extremity, lower extremity, or axial spine, or were at risk of RPOA; diagnosis of OA was guided by American College of Rheumatology (ACR) criteria with radiologic assessment at the discretion of the investigator. However, because there was no protocol-mandated imaging in the study after screening, it is possible that there were undetected cases of RPOA1. Furthermore, given that RPOA is usually observed after 24 weeks of exposure, the duration of this study was not long enough to rule this out; we did not observe any case of subchondral insufficiency fracture in any of the large joints.\u003C\/p\u003E\u003Cp id=\u0022p-55\u0022\u003EAnti-NGF monoclonal antibodies have been associated with adverse effects such as sensory abnormalities (including paraesthesia, hypoesthesia or burning sensation) in clinical studies (\u003Cem\u003E\u003Ca id=\u0022xref-ref-15-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-26-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E\u003C\/em\u003E), and with effects on autonomic nervous system and sympathetic dysfunction in non-clinical studies. While the incidence of such events in the present study was generally higher among MEDI7352-treated patients than in placebo-treated patients, the absolute number of patients experiencing such events was small. We hypothesise that the lower dose (and consequently, lower levels of NGF suppression) with MEDI7352 may result in fewer such adverse effects when compared with using an anti-NGF monoclonal antibody alone, at a higher dose \u2013 while still maintaining a clinically meaningful benefit.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003EAnti-TNF\u03b1 therapies have been previously associated with an increased risk of serious or severe infections (\u003Cem\u003E\u003Ca id=\u0022xref-ref-37-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-37\u0022\u003E37\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-38-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E\u003C\/em\u003E). Infections and infestations were commonly reported TEAEs in this study; this included common infections such as upper respiratory tract infection, urinary tract infection, and nasopharyngitis, which were all slightly more frequent in the placebo group. Overall, we observed no increased risk of infection due to MEDI7352, but again this is more likely to be observed with more chronic dosing \u2013 and is potentially a concern in a population of patients with diabetes who are more vulnerable to infection.\u003C\/p\u003E\u003Cp id=\u0022p-57\u0022\u003EAs with all biologics, there may be risks of immunological reactions including hypersensitivity reactions, injection site reactions, and the consequences of immunogenicity. Fewer than 4% of patients exposed to MEDI7352 developed an infusion-related reaction, compared with 0% in the placebo group; the reported events were mild or moderate, and patients recovered on the same or on the next day. Most of the patients treated with MEDI7352 did not experience an injection site reaction.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003EWe also compared the safety data from this present study with safety data from three other trials (not reported): a Phase 1 study to evaluate safety, tolerability, PK and immunogenicity of MEDI7352 in healthy volunteers (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04770428\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT04770428\u003C\/a\u003E), a Phase 1 study of MEDI7352 in patients with painful OA of the knee (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02508155\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT02508155\u003C\/a\u003E), and a Phase 2 study of the efficacy and safety of MEDI7352 in patients with painful OA of the knee (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04675034\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT04675034\u003C\/a\u003E). This analysis showed there was general consistency with the findings in the present study. MEDI7352 was generally well tolerated across all four studies; all adverse events have been reported on clinicaltrials.gov. Of note, in the Phase 2 trial in patients with painful OA of the knee (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04675034\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT04675034\u003C\/a\u003E), there were two events of rapidly progressive osteoarthritis type 1 (RPOA1) in the placebo group (one left knee, one right knee), one event of RPOA type 1 in the MEDI7352 Dose Level 4 group (left knee), and one of a subchondral insufficiency fracture in the MEDI7352 Dose Level 2 group (left hip). There were no overall differences in the incidence of \u2018infections and infestations\u2019. We also noted an increase in peripheral sensory symptoms (paraesthesia\/hypoesthesia) in the OA study that are well described in other NGF programs and were self-limiting. There was one case of a new neuropathy that was treatment-emergent in the MEDI7352 Dose Level 4 group (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT04675034\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022\u003ENCT04675034\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EIn this study, we observed a high prevalence of ADAs \u2013 consistent with observations in other studies of MEDI7352. The presence of ADAs appeared to impact both PK and PD of MEDI7352, and likely confounded our ability to accurately assess free NGF suppression. A detailed population PK\/PD modelling analysis of MEDI7352 PK and total NGF serum concentrations indicates that at the dose of 450 \u03bcg\/kg once every two weeks for 12 weeks, predicted levels of free NGF suppression were approximately 50% \u2013 substantially lower than the predicted levels of free NGF suppression in other studies of anti-NGF antibodies in PDN (\u003Cem\u003E\u003Ca id=\u0022xref-ref-32-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-32\u0022\u003E32\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-33-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E\u003C\/em\u003E); a post hoc analysis indicated that we observed no correlation between ADA levels and lack of efficacy, at least with this limited dataset.\u003C\/p\u003E\u003Cp id=\u0022p-60\u0022\u003EThe study was disrupted by Covid-19 (resulting in a temporary pause), and a notable limitation is the relatively low number of patients enrolled, which also impacted our ability to detect a dose-response. Overall, 53 patients were exposed to MEDI7352, with only 4 patients included in the analysis sets for MEDI7352 5\u03bcg\/kg. Therefore, any conclusions on safety need to be evaluated from the perspective of a relatively low sample size and short study duration of 12 weeks.\u003C\/p\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EConclusions\u003C\/h3\u003E\u003Cp id=\u0022p-61\u0022\u003EMEDI7352 is a novel bispecific fusion protein designed to target two key mediators in pain signalling pathways, NGF and TNF\u03b1. This unique mechanism has previously demonstrated synergy in pre-clinical models of both inflammatory and neuropathic pain, at unexpectedly low dose; a previous Phase 1 study in patients with painful OA of the knee indicated potential for analgesic efficacy. Combining these data suggest the potential for a paradigm-changing treatment for patients with chronic pain, without the previous dose-limiting safety concerns of the anti-NGF mAb approaches.\u003C\/p\u003E\u003Cp id=\u0022p-62\u0022\u003EMEDI7352 at a dose of 450 \u03bcg\/kg every two weeks over a treatment period of 12 weeks provided a statistically significant and clinically meaningful reduction of pain compared with placebo, in patients who were on a background of permitted standard-of-care concomitant analgesic medications. The majority of patients in this group had at least a 30% decrease of their pain, with a significant proportion also experiencing a 50% reduction in pain. Overall, the safety profile of MEDI7352 was similar to that of placebo, with no unexpected safety findings. MEDI7352 has so far not shown a propensity to be associated with joint-related adverse events as observed with anti NGF monoclonal antibodies, but this should be caveated to note that joint-related adverse events tend to be seen after 24 weeks of dosing. The significant pain reduction provided by MEDI7352 in patients with PDN (who remained on standard of care) could potentially change the treatment paradigm for this difficult-to-treat population.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-9\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMATERIALS AND METHODS\u003C\/h2\u003E\u003Cdiv id=\u0022sec-10\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStudy design\u003C\/h3\u003E\u003Cp id=\u0022p-63\u0022\u003EThis was a randomised, double-blind, placebo-controlled, exploratory, Phase 2a, multicentre study of MEDI7352 in patients aged 18 years and older with moderate to severe chronic PDN, persistent for 6 months or longer, not adequately controlled by standard of care treatments, caused by type 1 or type 2 diabetes mellitus. Trial registration: \u003Ca href=\u0022https:\/\/clinicaltrials.gov\/study\/NCT03755934\u0022\u003Ehttps:\/\/clinicaltrials.gov\/study\/NCT03755934\u003C\/a\u003E (date first submitted: 31 October 2018). Patients or the public were not involved in the design, conduct or reporting of this trial.\u003C\/p\u003E\u003Cp id=\u0022p-64\u0022\u003EThe study was conducted at 48 sites in 6 countries (the United Kingdom, Hungary, Poland, Romania, Denmark, and Spain; no patients were enrolled in Denmark or Spain), in a hospital setting. First subject enrolled November 2018, last subject last visit June 2023.\u003C\/p\u003E\u003Cp id=\u0022p-65\u0022\u003EThe study was performed in accordance with the ethical principles aligned with the Declaration of Helsinki, and in compliance with International Council for Harmonisation (ICH) Good Clinical Practice, including the archiving of essential documents. Written informed consent was obtained from all patients prior to enrolment.\u003C\/p\u003E\u003Cp id=\u0022p-66\u0022\u003EThe primary objective was to assess the efficacy of MEDI7352 vs placebo on chronic pain in patients with PDN currently taking standard of care medication for their PDN pain. The secondary objectives were to assess safety, tolerability, pharmacokinetics and pharmacodynamics, immunogenicity, and dose-response of MEDI7352 in patients with PDN.\u003C\/p\u003E\u003Cp id=\u0022p-67\u0022\u003EThe study incorporated a screening period of up to 45 days and a 12-week double-blind treatment period during which MEDI7352 or placebo was administered intravenously on 6 occasions, with each dose separated by 14 days. There was a 6-week follow-up period (Fig. S1).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPatient population\u003C\/h3\u003E\u003Cp id=\u0022p-68\u0022\u003EKey inclusion criteria were: male, or post-menopausal or surgically sterile females; 18 to 80 years of age (inclusive) on day of randomization; body mass index of \u226442 kg\/m\u003Csup\u003E2\u003C\/sup\u003E; chronic pain associated with PDN with mean pain intensity score of \u22654, as measured on an 11-point (0 to 10) NRS; willing and able to discontinue all nonsteroidal anti-inflammatory drug or cyclooxygenase2 analgesic therapy; taking medication for the treatment of PDN. Patients had to be taking at least 1 of the first-line medications (consistent with regional or local standard of care guidelines for PDN) belonging to either the anticonvulsant class (pregabalin or gabapentin) or the antidepressant class (duloxetine, venlafaxine, or amitriptyline), but no more than 1 medication from a single class. During the study, NSAIDs, analgesic doses of aspirin, and Cox-2 inhibitors were prohibited.\u003C\/p\u003E\u003Cp id=\u0022p-69\u0022\u003EKey exclusion criteria were: other clinically significant neuropathy; diagnosis of clinically significant OA (affecting a major joint in the upper or lower extremity or axial spine; or other degenerative disease affecting any joint in subjects for whom, in the opinion of the investigator, there was an identified risk of osteonecrosis, RPOA, subchondral insufficiency fractures, neurogenic arthropathy, or analgesia-induced arthropathy); other chronic pain conditions; major psychiatric disorders; significant cardiovascular or lung disease; clinically important infections; other serious illnesses.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EInterventions, randomization and blinding\u003C\/h3\u003E\u003Cp id=\u0022p-70\u0022\u003EFour study Stages were planned (Fig. S1.). Patients in Stage 1 were to be randomly assigned to placebo or the lowest dose of MEDI7352 (5 \u03bcg\/kg) until at least 10 patients had been recruited. In Stage 2, up to a maximum of 30 patients were to be randomly assigned to placebo or MEDI7352 150 \u03bcg\/kg. In Stage 3, approximately 67 patients were to be randomly assigned in a 1:1 ratio to placebo or MEDI7352 450 \u03bcg\/kg to ensure sufficient patients were evaluable for the pre-planned interim analysis.\u003C\/p\u003E\u003Cp id=\u0022p-71\u0022\u003EAdministrative analyses were conducted during Stage 3 to confirm decision-making for Stage 4 with respect to exact sample size and dose allocation ratio. Upon completing enrolment for Stage 3, an interim analysis was to be performed before Stage 4. Approximately 165 eligible patients were planned to be randomly assigned to treatment with equal allocation across 3 dose levels of MEDI7352 or placebo in Stage 4, to ensure that approximately 236 patients were evaluable for the efficacy analysis of Stages 2 to 4 combined.\u003C\/p\u003E\u003Cp id=\u0022p-72\u0022\u003EAfter all patients in Stage 3 completed the study, the sponsor decided to prematurely terminate the study because enrolment was taking longer than anticipated, making it challenging to progress with the current protocol to Stage 4. The sponsor halted screening activities on 12 January 2023 and informed sites about the study termination on 11 April 2023. Ongoing patients continued on treatment until end of the study and the required follow-up period as per protocol. A 50 \u03bcg\/kg dose planned for Stage 4 was not evaluated.\u003C\/p\u003E\u003Cp id=\u0022p-73\u0022\u003EThe randomization schedule was computer-generated by Premier Research before the study, using a permuted block algorithm. No one involved in the performance of the study had access to the randomisation schedule before official unblinding of treatment assignment. All patients, investigators, and study personnel involved in the conduct of the study, including data management, were blinded to treatment assignment \u2013 with the exception of a specified unblinded statistician and programmer from Premier Research, unblinded site monitors and clinical managers from Premier Research, and an unblinded pharmacist at each site. Unblinded personnel did not participate in study procedures or data analysis prior to unblinding. Data were prepared for review and interim analysis by unblinded personnel who were not otherwise involved in the conduct of the study.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEfficacy assessments\u003C\/h3\u003E\u003Cp id=\u0022p-74\u0022\u003EThe primary efficacy endpoint was change in the weekly average of the average daily pain scores from the baseline week to Week 12 of MEDI7352 compared with placebo, as measured on an 11-point (0 to 10) NRS. Key secondary endpoints were 1) Change in the weekly average of the average daily pain score, as measured on an 11-point (0 to 10) NRS, from baseline to Weeks 2, 4, 6, 8, and 10 of treatment and the week before the follow-up visit; 2) Percentage of patients who achieved \u226530% and \u226550% reductions in the weekly average of the average daily pain score from baseline during Weeks 4, 8, and 12 of treatment and the week before follow-up; 3) Change in Daily Sleep Interference Scale from baseline to Days 28, 56, and 84 of treatment and the follow-up visit; 4) Change in Galer Neuropathic Pain Scale from baseline to Days 28, 56, and 84 of treatment and the follow-up visit; 5) Proportion of patients who have \u2018improved\u2019, \u2018much improved\u2019, or \u2018very much improved\u2019 relative to baseline on the PGIC on Days 28, 56, and 84 of treatment and the follow-up visit; 6) Change in 36-Item Short-form Health Survey from baseline to Day 84 of treatment; 7) Change in the amount of rescue medication used (in terms of dosage\/day) from baseline to Week 12 of treatment.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ESafety and adverse event assessments\u003C\/h3\u003E\u003Cp id=\u0022p-75\u0022\u003ESafety and tolerability assessments included: Adverse Events (AEs) and serious AEs, physical and neurological examinations, neuropathy assessments (Total Neuropathy Score-Nurse), strength (dorsiflexion) and deep tendon reflex (knee and ankle) assessments, vital signs, 12-lead electrocardiograms, clinical laboratory testing (hematology, clinical chemistry, coagulation, and urinalysis), motor and sensory nerve conduction, concomitant medication assessment, injection-site reaction assessment, and infusion reaction assessments.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPharmacokinetic, pharmacodynamic, immunogenicity and dose-response assessments\u003C\/h3\u003E\u003Cp id=\u0022p-76\u0022\u003EPharmacokinetic parameters to be assessed for MEDI7352 were to include Cmax, time of Cmax, area under the serum concentration-time curve from time 0 to infinity, area under the serum concentration-time curve from time 0 to the time of the last quantifiable serum concentration, area under the serum concentration-time curve for the dosing interval at steady state, Cmax at steady state, volume of distribution at steady state, half-life, and total body clearance at steady state.\u003C\/p\u003E\u003Cp id=\u0022p-77\u0022\u003EPharmacodynamics assessments included NGF measurements. Other assessments included immunogenicity (ADA) and dose response.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical Analysis\u003C\/h3\u003E\u003Cp id=\u0022p-78\u0022\u003EApproximately 272 eligible patients were planned to be randomly assigned to double-blind treatment with 1 of 4 dose levels of MEDI7352 (5, 50, 150, and 450 \u03bcg\/kg, dependent upon the stage of the study) or placebo, to ensure that approximately 236 patients were eligible for the efficacy analysis of Stages 2, 3, and 4 combined. There was no formal sample size calculation for stage 1; 10 patients in Stage 1 were considered sufficient for the initial assessment of safety. The sample size for Stages 2 to 4 combined was determined by a formal power calculation (see below) and the size of Stage 3 was defined to confirm decision-making for the Stage 4 sample size and dose allocation ratio.\u003C\/p\u003E\u003Cp id=\u0022p-79\u0022\u003EThis study was powered at greater than 80% to detect a statistically significant (1-sided alpha = 0.025) dose-response relationship when the true Week 12 placebo-corrected change from baseline difference at the 450 \u03bcg\/kg dose was 1.25 on the 11-point NRS scale (MEDI7352-placebo treatment) and the true dose-response followed a hyperbolic maximum effect of the drug (E\u003Csub\u003Emax\u003C\/sub\u003E) relationship, with the dose to achieve 50% of the maximum effect (ED50) within the range of 1 to 750 \u03bcg\/kg. This calculation also assumed: 1) The true standard deviation was 2.4, based on other studies with pregabalin in PDN. 2) Data from Stages 2, 3, and 4 would be combined so that the number of patients evaluable for the dose-response analysis was 236. The total number of patients evaluable for efficacy for the placebo, 50, 150, and 450 \u03bcg\/kg doses of MEDI7352 would be equal to 81, 37, 51 and 67, respectively. 3) The dose-response hypothesis test was multiplicity adjusted in order to control the type 1-error.\u003C\/p\u003E\u003Cp id=\u0022p-80\u0022\u003EThe study included 4 analysis populations: 1) Screening: all subjects who provided informed consent and\/or assent and provided demographic and\/or baseline screening assessments, regardless of their randomization and treatment status in the study. 2) Safety: all patients who received at least 1 dose of double-blind study medication. 3) mITT: used for all efficacy analyses and included all randomized patients who received at least 1 dose of double-blind study medication and had at least 1 post-baseline NRS assessment. 4) PK population included all patients for whom a PK sample was obtained and analysed. Patients receiving placebo were not included in the summary and analysis of PK parameters.\u003C\/p\u003E\u003Cp id=\u0022p-81\u0022\u003EEfficacy, safety and tolerability data were summarised descriptively. Primary and secondary endpoint efficacy data were tabulated according to the \u2018observed cases\u2019 approach. In addition, if there were missing data at a key analysis time point (Weeks 4, 8, and 12), then results were also tabulated according to LOCF and baseline observation carried forward (BOCF).\u003C\/p\u003E\u003Cp id=\u0022p-82\u0022\u003EThe main statistical analysis of the primary efficacy endpoint at Week 12 used the multiple comparison procedure modelling approach (MCP-MOD) on LOCF data, which is a well-established statistical methodology for establishing both the existence of a dose response and modelling the underlying dose-response relationship. The underlying model was an ANCOVA with dependent variable \u2018CFB to Week 12 (LOCF)\u2019, and independent variables included: dose group as a factor variable with the placebo group as the reference level, baseline score (i.e. baseline weekly average pain [NRS]) as a continuous variable, and co-medication type.\u003C\/p\u003E\u003Cp id=\u0022p-83\u0022\u003EIn addition, changes from baseline in continuous endpoints were compared between treatment groups using mixed models for repeated measures including terms for treatment (as a factor), time point (as a factor), the interaction between treatment and time point, and the baseline value of the variable undergoing analysis. Binary outcomes were analysed using generalised estimating equations, with the models including the same terms as the mixed models repeated measures. Other non-binary categorical endpoints were analysed using Cochran-Mantel-Haenszel statistics for stratified data. The detailed statistical analysis plan and protocol of this trial are available at: \u003Ca href=\u0022https:\/\/www.astrazenecaclinicaltrials.com\/study\/D5680C00002\/\u0022\u003Ehttps:\/\/www.astrazenecaclinicaltrials.com\/study\/D5680C00002\/\u003C\/a\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-17\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-84\u0022\u003EData which is not restricted by confidentiality considerations are available on reasonable request to the authors\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-18\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EFunding\u003C\/h2\u003E\u003Cp id=\u0022p-86\u0022\u003EThe studies reported in this manuscript were funded by AstraZeneca.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-19\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAuthor contributions\u003C\/h2\u003E\u003Cp id=\u0022p-87\u0022\u003EConceptualization: IC, FW, TC, TO, NB, MP\u003C\/p\u003E\u003Cp id=\u0022p-88\u0022\u003EMethodology: IC, FW, TC, TO, TS, AG, KT, IP, NB, EP\u003C\/p\u003E\u003Cp id=\u0022p-89\u0022\u003EInvestigation: FW, TC, KMS, DH, TO, TS, AG, OA, KT, IP, DH, JL, NB, EP\u003C\/p\u003E\u003Cp id=\u0022p-90\u0022\u003EFunding acquisition: FW, IC, MP\u003C\/p\u003E\u003Cp id=\u0022p-91\u0022\u003EProject administration: FW\u003C\/p\u003E\u003Cp id=\u0022p-92\u0022\u003ESupervision: FW, IC, MP, TO, EP\u003C\/p\u003E\u003Cp id=\u0022p-93\u0022\u003EWriting \u2013 original draft: FW, IC, KMS, EE\u003C\/p\u003E\u003Cp id=\u0022p-94\u0022\u003EWriting \u2013 review \u0026amp; editing: All authors\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-20\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECompeting interests\u003C\/h2\u003E\u003Cp id=\u0022p-95\u0022\u003EKMS, OA, TC, TO, EE, EP, DH, RJ, MP, KT, IP, FW, MAP and IC are employees or former employees of AstraZeneca and may own shares. AG is a shareholder of BICL, LLC and consultant to Novartis, TissueGene, Coval, Paradigm, Peptinov, Scarcell, Levicept, Pacira, ICM, Medipost, 4Moving and Formation Bio.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-21\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData and materials availability\u003C\/h2\u003E\u003Cp id=\u0022p-96\u0022\u003EThe trial clinical study report synopsis, protocol, statistical analysis plan, and results are all available at: \u003Ca href=\u0022https:\/\/www.astrazenecaclinicaltrials.com\/study\/D5680C00002\/\u0022\u003Ehttps:\/\/www.astrazenecaclinicaltrials.com\/study\/D5680C00002\/\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgments\u003C\/h2\u003E\u003Cp id=\u0022p-85\u0022\u003EThe authors would like to thank the participants, the site investigators, and the site staff who participated in the trials. The authors also thank Stanislav Ignatenko for Phase 1 (SAD\/MAD), Jon Hatcher and Darren Schofield for their work to construct and pre-clinically characterize MEDI7352, and Andreas Leidenroth of Larkfields Ltd for medical writing support.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EREFERENCES\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.1\u0022 data-doi=\u002210.1016\/S0140-6736(23)01301-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EGlobal Burden of Disease 2021 Diabetes Collaboration\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EGlobal, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E402\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E203\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E234\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%26rft.volume%253D402%26rft.spage%253D203%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252823%252901301-6%26rft_id%253Dinfo%253Apmid%252F37356446%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0140-6736(23)01301-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=37356446\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVeves\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBackonja\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMalik\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPainful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPain Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E660\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E674\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPain%2BMed%26rft.volume%253D9%26rft.spage%253D660%26rft_id%253Dinfo%253Apmid%252F18828198%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=18828198\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.3\u0022 data-doi=\u002210.1016\/S0168-8227(99)00112-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGaler\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGianas\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. P.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJensen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPainful diabetic polyneuropathy: epidemiology, pain description, and quality of life\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiabetes Res Clin Pract\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E47\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E123\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E128\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2000\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDiabetes%2Bresearch%2Band%2Bclinical%2Bpractice%26rft.stitle%253DDiabetes%2BRes%2BClin%2BPract%26rft.aulast%253DGaler%26rft.auinit1%253DB.%2BS.%26rft.volume%253D47%26rft.issue%253D2%26rft.spage%253D123%26rft.epage%253D128%26rft.atitle%253DPainful%2Bdiabetic%2Bpolyneuropathy%253A%2Bepidemiology%252C%2Bpain%2Bdescription%252C%2Band%2Bquality%2Bof%2Blife.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0168-8227%252899%252900112-6%26rft_id%253Dinfo%253Apmid%252F10670912%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0168-8227(99)00112-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10670912\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000084847000007\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.4\u0022 data-doi=\u002210.2337\/diacare.26.6.1790\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGordois\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScuffham\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShearer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOglesby\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETobian\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EThe health care costs of diabetic peripheral neuropathy in the US\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiabetes Care\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E26\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1790\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1795\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDiabetes%2BCare%26rft.stitle%253DDiabetes%2BCare%26rft.aulast%253DGordois%26rft.auinit1%253DA.%26rft.volume%253D26%26rft.issue%253D6%26rft.spage%253D1790%26rft.epage%253D1795%26rft.atitle%253DThe%2BHealth%2BCare%2BCosts%2Bof%2BDiabetic%2BPeripheral%2BNeuropathy%2Bin%2Bthe%2BU.S.%26rft_id%253Dinfo%253Adoi%252F10.2337%252Fdiacare.26.6.1790%26rft_id%253Dinfo%253Apmid%252F12766111%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiZGlhY2FyZSI7czo1OiJyZXNpZCI7czo5OiIyNi82LzE3OTAiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNS8xMS8zMC8yMDI1LjExLjI3LjI1MzQxMTU5LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.5\u0022 data-doi=\u002210.1007\/BF00400697\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYoung\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoulton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMacLeod\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWilliams\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESonksen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EA multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDiabetologia\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E150\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E154\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E1993\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDiabetologia%26rft.stitle%253DDiabetologia%26rft.aulast%253DYoung%26rft.auinit1%253DM.%2BJ.%26rft.volume%253D36%26rft.issue%253D2%26rft.spage%253D150%26rft.epage%253D154%26rft.atitle%253DA%2Bmulticentre%2Bstudy%2Bof%2Bthe%2Bprevalence%2Bof%2Bdiabetic%2Bperipheral%2Bneuropathy%2Bin%2Bthe%2BUnited%2BKingdom%2Bhospital%2Bclinic%2Bpopulation.%26rft_id%253Dinfo%253Adoi%252F10.1007%252FBF00400697%26rft_id%253Dinfo%253Apmid%252F8458529%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1007\/BF00400697\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=8458529\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1993KH64700011\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.6\u0022 data-doi=\u002210.1177\/2040622314552071\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJaved\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI. N.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPetropoulos\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EU.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAlam\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMalik\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETreatment of painful diabetic neuropathy\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETher Adv Chronic Dis\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E15\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E28\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTher%2BAdv%2BChronic%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1177%252F2040622314552071%26rft_id%253Dinfo%253Apmid%252F25553239%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1177\/2040622314552071\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25553239\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESultan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGaskell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDerry\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMoore\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EDuloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Neurol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E, \u003Cspan class=\u0022cit-issue\u0022\u003E29\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDimitroulas\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELambe\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKlocke\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKitas\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. V.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDuarte\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EBiologic drugs as analgesics for the management of osteoarthritis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESemin Arthritis Rheum\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E46\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E687\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E691\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSemin%2BArthritis%2BRheum%26rft.volume%253D46%26rft.spage%253D687%26rft_id%253Dinfo%253Apmid%252F28063649%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=28063649\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.9\u0022 data-doi=\u002210.1016\/j.tips.2005.12.001\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHefti\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERosenthal\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWalicke\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWyatt\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVergara\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShelton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavies\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ENovel class of pain drugs based on antagonism of NGF\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETrends Pharmacol Sci\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E85\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E91\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTrends%2Bin%2BPharmacological%2BSciences%2B%2528Regular%2Bed.%2529%26rft.stitle%253DTrends%2Bin%2BPharmacological%2BSciences%2B%2528Regular%2Bed.%2529%26rft.aulast%253DHefti%26rft.auinit1%253DF.%2BF.%26rft.volume%253D27%26rft.issue%253D2%26rft.spage%253D85%26rft.epage%253D91%26rft.atitle%253DNovel%2Bclass%2Bof%2Bpain%2Bdrugs%2Bbased%2Bon%2Bantagonism%2Bof%2BNGF.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.tips.2005.12.001%26rft_id%253Dinfo%253Apmid%252F16376998%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.tips.2005.12.001\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=16376998\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000236043000005\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELeung\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECahill\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETNF-\u03b1 and neuropathic pain - a review\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Neuroinflammation\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E, \u003Cspan class=\u0022cit-issue\u0022\u003E27\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.11\u0022 data-doi=\u002210.1002\/ana.410360221\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. G.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPetty\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECornblath\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAdornato\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhry\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFlexner\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWachsman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESinicropi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL. E.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBurton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPeroutka\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EThe effect of systemically administered recombinant human nerve growth factor in healthy human subjects\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Neurol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E244\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E246\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E1994\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnnals%2Bof%2Bneurology%26rft.stitle%253DAnn%2BNeurol%26rft.aulast%253DPetty%26rft.auinit1%253DB.%2BG.%26rft.volume%253D36%26rft.issue%253D2%26rft.spage%253D244%26rft.epage%253D246%26rft.atitle%253DThe%2Beffect%2Bof%2Bsystemically%2Badministered%2Brecombinant%2Bhuman%2Bnerve%2Bgrowth%2Bfactor%2Bin%2Bhealthy%2Bhuman%2Bsubjects.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fana.410360221%26rft_id%253Dinfo%253Apmid%252F8053664%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/ana.410360221\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=8053664\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1994PB26000020\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.12\u0022 data-doi=\u002210.1146\/annurev.neuro.29.051605.112929\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPezet\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. B.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMcMahon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ENeurotrophins: mediators and modulators of pain\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnnu Rev Neurosci\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E507\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E538\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnnual%2Breview%2Bof%2Bneuroscience%26rft.stitle%253DAnnu%2BRev%2BNeurosci%26rft.aulast%253DPezet%26rft.auinit1%253DS.%26rft.volume%253D29%26rft.spage%253D507%26rft.epage%253D538%26rft.atitle%253DNeurotrophins%253A%2Bmediators%2Band%2Bmodulators%2Bof%2Bpain.%26rft_id%253Dinfo%253Adoi%252F10.1146%252Fannurev.neuro.29.051605.112929%26rft_id%253Dinfo%253Apmid%252F16776595%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1146\/annurev.neuro.29.051605.112929\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=16776595\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000239807800018\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.13\u0022 data-doi=\u002210.1038\/nrd3930\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECroft\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBenedict\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWare\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EClinical targeting of the TNF and TNFR superfamilies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Rev Drug Discov\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E147\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E168\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat%2BRev%2BDrug%2BDiscov%26rft.volume%253D12%26rft.spage%253D147%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrd3930%26rft_id%253Dinfo%253Apmid%252F23334208%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/nrd3930\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23334208\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.14\u0022 data-doi=\u002210.7326\/0003-4819-156-8-201204170-00397\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. P.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECohen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWhite\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKurihara\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELarkin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGriffith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGilligan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELarkin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMorlando\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPasquina\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYaksh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENguyen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EEpidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Intern Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E156\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E551\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E559\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnnals%2Bof%2BInternal%2BMedicine%26rft.stitle%253DANN%2BINTERN%2BMED%26rft.aulast%253DCohen%26rft.auinit1%253DS.%2BP.%26rft.volume%253D156%26rft.issue%253D8%26rft.spage%253D551%26rft.epage%253D559%26rft.atitle%253DEpidural%2BSteroids%252C%2BEtanercept%252C%2Bor%2BSaline%2Bin%2BSubacute%2BSciatica%253A%2BA%2BMulticenter%252C%2BRandomized%2BTrial%26rft_id%253Dinfo%253Adoi%252F10.7326%252F0003-4819-156-8-201204170-00397%26rft_id%253Dinfo%253Apmid%252F22508732%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.7326\/0003-4819-156-8-201204170-00397\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22508732\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000303151800014\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.15\u0022 data-doi=\u002210.1016\/j.jpain.2012.05.006\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMurphy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERadin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavignon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Pain\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E790\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E798\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DThe%2Bjournal%2Bof%2Bpain%2B%253A%2B%2Bofficial%2Bjournal%2Bof%2Bthe%2BAmerican%2BPain%2BSociety%26rft.stitle%253DJ%2BPain%26rft.aulast%253DBrown%26rft.auinit1%253DM.%2BT.%26rft.volume%253D13%26rft.issue%253D8%26rft.spage%253D790%26rft.epage%253D798%26rft.atitle%253DTanezumab%2Breduces%2Bosteoarthritic%2Bknee%2Bpain%253A%2Bresults%2Bof%2Ba%2Brandomized%252C%2Bdouble-blind%252C%2Bplacebo-controlled%2Bphase%2BIII%2Btrial.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jpain.2012.05.006%26rft_id%253Dinfo%253Apmid%252F22784777%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jpain.2012.05.006\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22784777\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMurphy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERadin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavignon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArthritis Rheum\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E65\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1795\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1803\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DArthritis%2BRheum%26rft.volume%253D65%26rft.spage%253D1795%26rft_id%253Dinfo%253Apmid%252F23553790%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23553790\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000322155000015\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.17\u0022 data-doi=\u002210.1016\/j.pain.2011.05.003\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKatz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. G.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBorenstein\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBirbara\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBramson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENemeth\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EEfficacy and safety of tanezumab in the treatment of chronic low back pain\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPain\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E152\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2248\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2258\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPain%26rft.stitle%253DPain%26rft.aulast%253DKatz%26rft.auinit1%253DN.%26rft.volume%253D152%26rft.issue%253D10%26rft.spage%253D2248%26rft.epage%253D2258%26rft.atitle%253DEfficacy%2Band%2Bsafety%2Bof%2Btanezumab%2Bin%2Bthe%2Btreatment%2Bof%2Bchronic%2Blow%2Bback%2Bpain.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.pain.2011.05.003%26rft_id%253Dinfo%253Apmid%252F21696889%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.pain.2011.05.003\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=21696889\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000295213700014\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.18\u0022 data-doi=\u002210.1016\/j.pain.2013.03.006\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKivitz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGimbel\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBramson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENemeth\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKeller\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVerburg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EEfficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPain\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E154\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1009\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1021\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPain%26rft.volume%253D154%26rft.spage%253D1009%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.pain.2013.03.006%26rft_id%253Dinfo%253Apmid%252F23628600%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.pain.2013.03.006\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23628600\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.19\u0022 data-doi=\u002210.1056\/NEJMoa0901510\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN. E.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELane\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchnitzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBirbara\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMokhtarani\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EShelton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ETanezumab for the treatment of pain from osteoarthritis of the knee\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E363\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1521\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1531\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.aulast%253DLane%26rft.auinit1%253DN.%2BE.%26rft.volume%253D363%26rft.issue%253D16%26rft.spage%253D1521%26rft.epage%253D1531%26rft.atitle%253DTanezumab%2Bfor%2Bthe%2Btreatment%2Bof%2Bpain%2Bfrom%2Bosteoarthritis%2Bof%2Bthe%2Bknee.%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa0901510%26rft_id%253Dinfo%253Apmid%252F20942668%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa0901510\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20942668\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000282887100006\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.20\u0022 data-doi=\u002210.1001\/jama.2019.8044\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchnitzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEaston\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELevinson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPixton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EViktrup\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavignon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVerburg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E322\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E37\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E48\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft.volume%253D322%26rft.spage%253D37%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2019.8044%26rft_id%253Dinfo%253Apmid%252F31265100%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.2019.8044\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31265100\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.11.27.25341159v1.21\u0022 data-doi=\u002210.1136\/annrheumdis-2013-204905\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchnitzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEkman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESpierings\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGreenberg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVerburg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EEfficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Rheum Dis\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E74\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1202\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1211\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fannrheumdis-2013-204905%26rft_id%253Dinfo%253Apmid%252F24625625%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjk6Ijc0LzYvMTIwMiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDI1LzExLzMwLzIwMjUuMTEuMjcuMjUzNDExNTkuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.22\u0022 data-doi=\u002210.1016\/j.pain.2013.04.035\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. L. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESpierings\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFidelholtz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWolfram\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. D.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EA phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPain\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E154\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1603\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1612\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPain%26rft.volume%253D154%26rft.spage%253D1603%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.pain.2013.04.035%26rft_id%253Dinfo%253Apmid%252F23707270%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.pain.2013.04.035\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23707270\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECarrino\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. E.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMcAlindon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchnitzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGuermazi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHochberg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. G.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EConaghan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBurr\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFountaine\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPixton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EViktrup\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVerburg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ECharacterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOsteoarthritis Cartilage\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E31\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1612\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1626\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOsteoarthritis%2BCartilage%26rft.volume%253D31%26rft.spage%253D1612%26rft_id%253Dinfo%253Apmid%252F37652258%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=37652258\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKrautmann\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWalters\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECole\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETena\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBergeron\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMessamore\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMwangi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERai\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDominowski\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESaad\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGuillot\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChouinard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ELaboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EVet J\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E276\u003C\/span\u003E, \u003Cspan class=\u0022cit-issue\u0022\u003E105733\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-25-1\u0022 title=\u0022View reference 25. in text\u0022 id=\u0022ref-25\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EReid\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGildea\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavies\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScott\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EMeasuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Vet Sci\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1395360\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2024\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DFront%2BVet%2BSci%26rft.volume%253D11%26rft.spage%253D1395360%26rft_id%253Dinfo%253Apmid%252F39205806%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=39205806\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26. in text\u0022 id=\u0022ref-26\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.26\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBerenbaum\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchnitzer\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKivitz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EViktrup\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHickman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPixton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrown\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDavignon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWest\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EGeneral Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EArthritis Care Res\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E74\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E918\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E928\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DArthritis%2BCare%2BRes%26rft.volume%253D74%26rft.spage%253D918%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E27.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-27-1\u0022 title=\u0022View reference 27. in text\u0022 id=\u0022ref-27\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.27\u0022 data-doi=\u002210.1097\/j.pain.0000000000001625\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESchmelz\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMantyh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMalfait\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFarrar\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EYaksh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETive\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EViktrup\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ENerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPain\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E160\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2210\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2220\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPain%26rft.volume%253D160%26rft.spage%253D2210%26rft_id%253Dinfo%253Adoi%252F10.1097%252Fj.pain.0000000000001625%26rft_id%253Dinfo%253Apmid%252F31145219%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1097\/j.pain.0000000000001625\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31145219\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E28.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 28. in text\u0022 id=\u0022ref-28\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.28\u0022 data-doi=\u002210.1038\/s41467-024-47633-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELai\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJiao\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ENerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat Commun\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E3225\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2024\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat%2BCommun%26rft.volume%253D15%26rft.spage%253D3225%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41467-024-47633-6%26rft_id%253Dinfo%253Apmid%252F38622181%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41467-024-47633-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=38622181\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E29.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-29-1\u0022 title=\u0022View reference 29. in text\u0022 id=\u0022ref-29\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.29\u0022 data-doi=\u002210.1136\/ard.2008.097048\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EU.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EM\u00f8ller D\u00f8hn\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoonen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. L.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHetland\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHansen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKnudsen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHansen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMadsen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHasselquist\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EM\u00f8ller\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003E\u00d8stergaard\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EErosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAnn Rheum Dis\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E68\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1585\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1590\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2008.097048%26rft_id%253Dinfo%253Apmid%252F19019887%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjEwOiI2OC8xMC8xNTg1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjUvMTEvMzAvMjAyNS4xMS4yNy4yNTM0MTE1OS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E30.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-30-1\u0022 title=\u0022View reference 30. in text\u0022 id=\u0022ref-30\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.30\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOstenfeld\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChessell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHammett\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EThornton\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGurrell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMcMahon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWelsh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChessell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003Epaper presented at the 10th Congress of the European Pain Federation, Copenhagen\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EDenmark\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E6\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E9\u003C\/span\u003E September \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E31.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 31. in text\u0022 id=\u0022ref-31\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.31\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWelsh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChessell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EIgnatenko\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKhan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGurrell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EOstenfeld\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPouliquen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV. P.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EReddy\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMaringwa\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZierhut\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EArends\u003C\/span\u003E\u003C\/span\u003E, I. \u003Cspan class=\u0022cit-article-title\u0022\u003EChessell, paper presented at the World Congress On Pain of the International Association for the Study of Pain (IASP), Toronto\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ECanada\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E19\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E23\u003C\/span\u003E September \u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E32.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-32-1\u0022 title=\u0022View reference 32. in text\u0022 id=\u0022ref-32\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.32\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESalem\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScott\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEmery\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWelsh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChessell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EClegg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKaschek\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPouliquen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E\u003Cspan class=\u0022cit-article-title\u0022\u003E, paper presented at the Congress of the American Conference on Pharmacometrics, Aurora\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EColorado\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E18\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EOctober\u003C\/span\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2025\u003C\/span\u003E (Abstract ID: 2111437).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E33.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-33-1\u0022 title=\u0022View reference 33. in text\u0022 id=\u0022ref-33\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.33\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESalem\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EScott\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EEmery\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWelsh\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EChessell\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EClegg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EW.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ETang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKaschek\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EPouliquen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E\u003Cspan class=\u0022cit-article-title\u0022\u003E, paper presented at the Congress of the American Conference on Pharmacometrics, Aurora\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EColorado\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E18\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E \u003Cspan class=\u0022cit-month\u0022\u003EOctober\u003C\/span\u003E \u003Cspan class=\u0022cit-pub-date\u0022\u003E2025\u003C\/span\u003E (Abstract ID: 2111439).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E34.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-34-1\u0022 title=\u0022View reference 34. in text\u0022 id=\u0022ref-34\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.34\u0022 data-doi=\u002210.1016\/j.jpainsymman.2007.09.016\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. K.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EVernon\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBrandenburg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. M.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAlvir\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGriesing\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. A.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERevicki\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EReliability, validity, and responsiveness of the daily sleep interference scale among diabetic peripheral neuropathy and postherpetic neuralgia patients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Pain Symptom Manage\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E54\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E68\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bpain%2Band%2Bsymptom%2Bmanagement%26rft.stitle%253DJ%2BPain%2BSymptom%2BManage%26rft.aulast%253DVernon%26rft.auinit1%253DM.%2BK.%26rft.volume%253D36%26rft.issue%253D1%26rft.spage%253D54%26rft.epage%253D68%26rft.atitle%253DReliability%252C%2Bvalidity%252C%2Band%2Bresponsiveness%2Bof%2Bthe%2Bdaily%2Bsleep%2Binterference%2Bscale%2Bamong%2Bdiabetic%2Bperipheral%2Bneuropathy%2Band%2Bpostherpetic%2Bneuralgia%2Bpatients.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jpainsymman.2007.09.016%26rft_id%253Dinfo%253Apmid%252F18411009%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.jpainsymman.2007.09.016\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=18411009\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000257688400007\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E35.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-35-1\u0022 title=\u0022View reference 35. in text\u0022 id=\u0022ref-35\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.35\u0022 data-doi=\u002210.1016\/S1474-4422(14)70251-0\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN. B.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EFinnerup\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAttal\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHaroutounian\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMcNicol\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBaron\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EDworkin\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGilron\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHaanp\u00e4\u00e4\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHansson\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EJensen\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. R.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EKamerman\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELund\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMoore\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. N.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERaja\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. S.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERice\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ERowbotham\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESena\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESiddall\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. H.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESmith\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWallace\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Neurol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E162\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E173\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%2BNeurol%26rft.volume%253D14%26rft.spage%253D162%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1474-4422%252814%252970251-0%26rft_id%253Dinfo%253Apmid%252F25575710%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1474-4422(14)70251-0\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25575710\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000347869400013\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E36.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-36-1\u0022 title=\u0022View reference 36. in text\u0022 id=\u0022ref-36\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.36\u0022 data-doi=\u002210.1016\/j.joca.2014.10.005\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. C.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EHochberg\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ESerious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EOsteoarthritis Cartilage\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E \u003Cspan class=\u0022cit-issue\u0022\u003ESuppl 1\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003ES18\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E21\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DOsteoarthritis%2BCartilage%26rft.volume%253D23%26rft.spage%253DS18%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.joca.2014.10.005%26rft_id%253Dinfo%253Apmid%252F25527216%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.joca.2014.10.005\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25527216\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E37.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-37-1\u0022 title=\u0022View reference 37. in text\u0022 id=\u0022ref-37\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.37\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EAtzeni\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ENucera\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EGerratana\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ECirillo\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMarino\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMiceli\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ESangari\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EBoccassini\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI. F.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMasala\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003EConcerns about the safety of anti-TNF agents when treating rheumatic diseases\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EExpert Opin Drug Saf\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E695\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E705\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DExpert%2BOpin%2BDrug%2BSaf%26rft.volume%253D19%26rft.spage%253D695%26rft_id%253Dinfo%253Apmid%252F32401624%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32401624\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F11%2F30%2F2025.11.27.25341159.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E38.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-38-1\u0022 title=\u0022View reference 38. in text\u0022 id=\u0022ref-38\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.11.27.25341159v1.38\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhang\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EX.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EMeng\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003EZhu\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-article-title\u0022\u003ERisk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront Pharmacol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E, \u003Cspan class=\u0022cit-issue\u0022\u003E746396\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}